113 related articles for article (PubMed ID: 32464356)
1. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.
Gallego-Arranz T; Pérez-Cantero A; Torrado-Salmerón C; Guarnizo-Herrero V; Capilla J; Torrado-Durán S
Colloids Surf B Biointerfaces; 2020 Sep; 193():111119. PubMed ID: 32464356
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation.
Moon C; Watts AB; Lu X; Su Y; Williams RO
Mol Pharm; 2019 May; 16(5):1799-1812. PubMed ID: 30925839
[TBL] [Abstract][Full Text] [Related]
3. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.
Veloso DFMC; Benedetti NIGM; Ávila RI; Bastos TSA; Silva TC; Silva MRR; Batista AC; Valadares MC; Lima EM
Drug Deliv; 2018 Nov; 25(1):1585-1594. PubMed ID: 30044149
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of the voriconazole loaded lipid-based nanoparticles.
Füredi P; Pápay ZE; Kovács K; Kiss BD; Ludányi K; Antal I; Klebovich I
J Pharm Biomed Anal; 2017 Jan; 132():184-189. PubMed ID: 27750101
[TBL] [Abstract][Full Text] [Related]
6. Formulation and characterization of voriconazole nanospray dried powders.
Chen R; Zhang T; Bao S; Liu Y; Xu X
Pharm Dev Technol; 2020 Sep; 25(7):815-822. PubMed ID: 32178565
[No Abstract] [Full Text] [Related]
7. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2015 Feb; 70(2):634-5. PubMed ID: 25488075
[No Abstract] [Full Text] [Related]
8. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
Dolton MJ; McLachlan AJ
Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
[TBL] [Abstract][Full Text] [Related]
9. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
[TBL] [Abstract][Full Text] [Related]
10. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
[TBL] [Abstract][Full Text] [Related]
12. Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Denning DW; Ghnan N; Kwizera R; Osmanov A
J Antimicrob Chemother; 2015 Feb; 70(2):633. PubMed ID: 25151206
[No Abstract] [Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
Bellmann R
Curr Pharm Des; 2013; 19(20):3629-47. PubMed ID: 23278532
[TBL] [Abstract][Full Text] [Related]
14. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.
Mello E; Posteraro B; Vella A; De Carolis E; Torelli R; D'Inzeo T; Verweij PE; Sanguinetti M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416538
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of non-irritant microemulsified voriconazole hydrogel system.
Raju Y P; N H; Chowdary V H; Nair RS; Basha D J; N T
Artif Cells Nanomed Biotechnol; 2017 Dec; 45(8):1539-1547. PubMed ID: 27887040
[TBL] [Abstract][Full Text] [Related]
17. Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis.
Rebong RA; Santaella RM; Goldhagen BE; Majka CP; Perfect JR; Steinbach WJ; Afshari NA
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7309-15. PubMed ID: 21849421
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
19. Fatal invasive pulmonary aspergillosis caused by voriconazole-resistant Aspergillus tubingensis in a patient with solid tumor.
Harada S; Ohkushi D; Nakano K; Mitani H; Yamamoto Y; Kamei K; Hayama B
J Infect Chemother; 2020 Mar; 26(3):301-304. PubMed ID: 31787529
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.
Rudramurthy SM; Seyedmousavi S; Dhaliwal M; Chakrabarti A; Meis JF; Mouton JW
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
